Health Economics›Essential thrombocythemia›First-line therapy

First-line therapy

Essential thrombocythemia · 6 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy

No data points — cost or PFS missing for current selection.

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Aspirin and Anagrelide Variant #01	—	R 3 050	28d	—	—	~2	~R 6 100 indirect	—
Anagrelide monotherapy Variant #01	—	R 3 030	28d	—	—	~2	~R 6 061 indirect	—
Hydroxyurea monotherapy Variant #01	—	R 265	28d	—	~243.6 mo	~2	~R 529 PFS proxy · indirect	—
Aspirin and Hydroxyurea Variant #01	—	R 9	28d	—	—	~2	~R 19 indirect	—
Peginterferon alfa-2a monotherapy Variant #01 Partial	—	—	7d	—	—	~2	—	—
Observation Partial	—	—	—	~10.3 mo	~37.1 mo	—	—	65

6 of 6 regimens shown